KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Debt: 2019-2025

Historic Non-Current Debt for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $8.6 billion.

  • Royalty Pharma's Non-Current Debt rose 29.58% to $8.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 billion, marking a year-over-year increase of 29.58%. This contributed to the annual value of $6.6 billion for FY2024, which is 7.81% up from last year.
  • Royalty Pharma's Non-Current Debt amounted to $8.6 billion in Q3 2025, which was up 22.31% from $7.0 billion recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Non-Current Debt peaked at $8.6 billion during Q3 2025, and registered a low of $5.8 billion during Q1 2021.
  • Over the past 3 years, Royalty Pharma's median Non-Current Debt value was $6.6 billion (recorded in 2024), while the average stood at $6.7 billion.
  • Its Non-Current Debt has fluctuated over the past 5 years, first declined by 13.78% in 2023, then climbed by 29.58% in 2025.
  • Royalty Pharma's Non-Current Debt (Quarterly) stood at $7.1 billion in 2021, then fell by 13.77% to $6.1 billion in 2022, then climbed by 0.27% to $6.1 billion in 2023, then grew by 7.81% to $6.6 billion in 2024, then grew by 29.58% to $8.6 billion in 2025.
  • Its Non-Current Debt was $8.6 billion in Q3 2025, compared to $7.0 billion in Q2 2025 and $6.6 billion in Q1 2025.